稳定干扰AGR2乳腺癌细胞系的建立及其功能

将AGR2基因的shRNA表达序列连接到pSUPER质粒中,获得pSUPER-shAGR2质粒,经测序鉴定后,将pSUPER-shAGR2和pSUPER质粒通过Lipofectamine2000转染MCF7细胞,经流式细胞仪和600μg.mL-1G418筛选获得稳定干扰AGR2的MCF7细胞系和对照细胞系,Western blot检测其RNA干扰效果,MTT检测细胞     

Modelling the role of dual specificity phosphatases in herceptin resistant breast cancer cell lines

BackgroundBreast cancer remains the most lethal type of cancer for women. A significant proportion of breast cancer cases are characterised by overexpression of the human epidermal growth factor receptor 2 protein (HER2). These cancers are commonly treated by Herceptin (Trastuzumab), but resistance to drug treatment frequently develops in tumour cells. Dual-specificity phosphatases (DUSPs) are thought to play a role in the mechanism of resistance, since some of them were reported to be overexpressed in tumours resistant to Herceptin.ResultsWe used a systems biology approach to investigate how DUSP overexpression could favour cell proliferation and to predict how this mechanism could be reversed by targeted inhibition of selected DUSPs. We measured the expression of 20 DUSP genes in two breast cancer cell lines following long-term (6 months) exposure to Herceptin, after confirming that these cells had become resistant to the drug. We constructed several Boolean models including specific substrates of each DUSP, and showed that our models correctly account for resistance when overexpressed DUSPs were kept activated. We then simulated inhibition of both individual and combinations of DUSPs, and determined conditions under which the resistance could be reversed.ConclusionsThese results show how a combination of experimental analysis and modelling help to understand cell survival mechanisms in breast cancer tumours, and crucially enable us to generate testable predictions potentially leading to new treatments of resistant tumours.     

Crosstalk events in the estrogen signaling pathway may affect tamoxifen efficacy in breast cancer molecular subtypes

Steroid hormones are involved on cell growth, development and differentiation. Such effects are often mediated by steroid receptors. One paradigmatic example of this coupling is the estrogen signaling pathway. Its dysregulation is involved in most tumors of the mammary gland. It is thus an important pharmacological target in breast cancer. This pathway, however, crosstalks with several other molecular pathways, a fact that may have consequences for the effectiveness of hormone modulating drug therapies, such as tamoxifen. For this work, we performed a systematic analysis of the major routes involved in crosstalk phenomena with the estrogen pathway – based on gene expression experiments (819 samples) and pathway analysis (493 samples) – for biopsy-captured tissue and contrasted in two independent datasets with in vivo and in vitro pharmacological stimulation. Our results confirm the presence of a number of crosstalk events across the estrogen signaling pathway with others that are dysregulated in different molecular subtypes of breast cancer. These may be involved in proliferation, invasiveness and apoptosis-evasion in patients. The results presented may open the way to new designs of adjuvant and neoadjuvant therapies for breast cancer treatment.     

Design,synthesis and biological activity against estrogen receptor-dependent breast cancer of furo[1]benzofuran derivatives

The docking study on a series of furo[1]benzofuran derivatives with ERα has been demonstrated. The synthesis and characterization of a series of furo[1]benzofuran derivatives were described. All the target compounds were conducted to in vitro for the inhibitory activities against human breast cancer strains T-47D, MCF-7 and toxicity against human liver normal cell strains HL7702 via MTT assay. Most of the target compounds possessed anti-estrogen receptor-dependent breast cancer activities with weak toxicity to healthy cell strains. The preliminary structure–activity relationships were discussed.     

人体乳腺癌组织红外光谱特征的研究

利用红外光谱法对正常乳腺组织、良性肿瘤和乳腺癌组织进行了对比研究.与正常组织的光谱相比,癌组织中蛋白质的某些氨基酸残基的ν_C-O(H)谱带位置明显向高波数位移,表明组织中该基团中的氢键大部分被破坏.蛋白质分子的氢键化的ν_NH谱带位置向低波数位移,且谱带形状也有所改变,说明NH…O=C氢键化程度增强.核酸的磷酸二酯基团的ν_s,PO₂^-谱带吸收强度明显增强,反映癌细胞内DNA相对含量增加;位于970cm^-1附近的ν_s,PO₃^{-谱带强度增加,提示细胞中磷酸化蛋白含量增加.而胶原蛋白的特征谱带强度减弱,说明其相对含量减少.研究证明,红外光谱可在分子水平上揭示乳腺肿瘤的特征.}     

乳腺癌病人单个细胞的Raman光谱

给出了乳腺癌病人正常乳腺细胞与癌细胞的拉曼光谱。从实验谱线中得到：癌变细胞的拉曼谱整体变弱, 就相对强度而言, DNA的2个磷酸根骨架峰782,1 084 cm-1和脱氧核糖-磷酸振动峰1 155及1 262 cm-1拉曼谱线明显的减少; 表征A型(DNA)构像的特征峰812 cm-1及谱线979,668 cm-1消失, 并有新峰1 175 cm-1出现, 905 cm-1的谱线增强并有6 cm-1的红移, 这说明DNA的磷酸根骨架有一定的断裂; 从而导致癌细胞的分裂繁殖失去有效的控制。在癌变组织细胞的拉曼谱中还发现了很强的一类与钙硬化密切相关的特征峰960 cm-1; 通过这些特征拉曼谱线的变化, 为癌症的诊断和治疗提供了有力的实验依据。     

Extraction and preconcentration of hemin from human blood serum and breast cancer supernatant

A green, facile, fast, and sensitive liquid‐phase microextraction method is presented for the extraction and preconcentration of hemin in the presence of free iron ions prior to flame atomic absorption spectroscopic determination. In this technique, an anion‐functionalized task‐specific ionic liquid is used as the extracting solvent. The interface between the extracting solvent and the bulk aqueous phase containing hemin is enormously enlarged by dispersing the ionic liquid to the aqueous phase with the help of ultrasound radiation. Hemin is selectively extracted into the ionic liquid after interaction with the functional group of the ionic liquid. Then, the concentration of the extracted hemin is determined through the absorbance of the iron ions contained in the hemin structure using flame atomic absorption spectroscopy. Different experimental parameters affecting the extraction efficiency have been optimized. Under the optimized conditions, the proposed method has a hemin concentration linear range of 0.020–0.80 mg/L with a detection limit of 0.0080 mg/L. This method has been successfully applied to the extraction and determination of hemin in human serum and supernatant samples.     

傅里叶变换红外光谱实时监测乳腺癌细胞化疗反应性的研究

应用傅里叶变换红外光谱技术监测乳腺癌细胞株MCF-7在化疗药物5氟尿嘧啶(5-FU)干预过程中相应的红外光谱变化,验证其与药物作用的时间和剂量相关性。对数据结果整理发现,在时间相关性方面,随药物作用时间的延长,乳腺癌细胞株MCF-7对脂类的利用率下降,细胞中脂类含量增加,同时肿瘤细胞分裂增殖受阻,细胞内DNA和RNA的含量降低,实验中观察到,48 h内,乳腺癌细胞MCF-7的红外光谱中代表脂类变化的峰强比I_{2 920}/I_{1 460}逐渐升高,I_{1 400}/I_{1 460}逐渐降低,代表细胞内核酸变化的峰强比I_{1 080}/I_{1 550},I_{1 240}/I_{1 550}逐渐降低;在剂量相关性方面,癌细胞红外光谱中峰强比I_{1 640}/I_{1 550}较正常升高,实验中观察到峰强比I_{1 640}/I_{1 550}随药物浓度的增加而呈现逐渐降低的趋势。以上这些变化与乳腺癌细胞在化疗药物干预过程中的生物学改变相符,可作为FTIR实时监测乳腺癌细胞化疗反应性的参考指标。     

Optimization and validation of stability indicating RP-HPLC method for the quantification of gefitinib in bulk drug and nanoformulations: An application towards in vitro and ex vivo performance evaluation

Gefitinib (GFB) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily to treat non-small cell lung cancer (NSCLC), but it also works by lowering AKT and MAPK phosphorylation, which makes it effective against the breast cancer cells. A high-performance liquid chromatography (HPLC) method was developed for detecting gefitinib by C18 analytical column with mobile phase containing acetonitrile and 1 % w/v ammonium acetate in water with ratio of 60:40. Box-Behnken design was used to optimize the chromatographic conditions, and method was validated for accuracy, precision, linearity, robustness, ruggedness, limit of detection, and limit of quantification. The developed method was found to be useful in estimating gefitinib in conventional marketed tablet dosage forms and nanoformulations such as SLNs and liposomes. With a calibration curve, linearity was attained in the drug concentration range of 8–56 µg/mL (r² = 0.9996), and sensitivity was found to be 1.3 and 3.9 µg/mLas LOD and LOQ, respectively. All the validation criteria for the method were within the acceptable limits. The drug content in the conventional tablet formulation was found to be 99.99 %. The HPLC analysis indicated that gefitinib was highly soluble in Precirol ATO5 as solid lipid and tween 80 as surfactant. Drug entrapment efficiency was found to be 83.1 % and 80.5 % for SLNs and liposomes respectively. In vitro release data revealed that 30 % of drug was released from plain suspension and more than 77 % released from both nanoformulations after 24 h at pH 7.4 respectively. By applying kinetic fit, data was most appropriately fitted into first order as compared to other. The apparent permeability of gefitinib from plain suspension, SLNs and Liposomes was found to be 3.98 × 10^?4 cm/min, 1.35 × 10^?4 cm/min and 1.79 × 10^?4 cm/min.     

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies

Breast cancer is one of the major impediments affecting women globally. The ATP-dependant heat shock protein 90 (Hsp90) forms the central component of molecular chaperone machinery that predominantly governs the folding of newly synthesized peptides and their conformational maturation. It regulates the stability and function of numerous client proteins that are frequently upregulated and/or mutated in cancer cells, therefore, making Hsp90 inhibition a promising therapeutic strategy for the development of new efficacious drugs to treat breast cancer. In the present in silico investigation, a structure-based pharmacophore model was generated with hydrogen bond donor, hydrogen bond acceptor and hydrophobic features complementary to crucial residues Ala55, Lys58, Asp93, Ile96, Met98 and Thr184 directed at inhibiting the ATP-binding activity of Hsp90. Subsequently, the phytochemical dataset of 3210 natural compounds was screened to retrieve the prospective inhibitors after rigorous validation of the model pharmacophore. The retrieved 135 phytocompounds were further filtered by drug-likeness parameters including Lipinski’s rule of five and ADMET properties, then investigated via molecular docking-based scoring. Molecular interactions were assessed using Genetic Optimisation for Ligand Docking program for 95 drug-like natural compounds against Hsp90 along with two clinical drugs as reference compounds – Geldanamycin and Radicicol. Docking studies revealed three phytochemicals are better than the investigated clinical drugs. The reference and hit compounds with dock scores of 48.27 (Geldanamycin), 40.90 (Radicicol), 73.04 (Hit1), 72.92 (Hit2) and 68.12 (Hit3) were further validated for their binding stability through molecular dynamics simulations. We propose that the non-macrocyclic scaffolds of three identified phytochemicals might aid in the development of novel therapeutic candidates against Hsp90-driven cancers.